Search results for "therapy."

showing 10 items of 12240 documents

Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and…

2016

A 52-year-old male patient was treated with standard radiochemotherapy with temozolomide for glioblastoma multiforme (GBM). After worsening of his clinical condition, further tumor-specific treatment was unlikely to be successful, and the patient seeked help from an alternative practitioner, who administered a combination of dichloroacetate (DCA) and artesunate (ART). A few days later, the patient showed clinical and laboratory signs of liver damage and bone marrow toxicity (leukopenia, thrombocytopenia). Despite successful restoration of laboratory parameters upon symptomatic treatment, the patient died 10 days after the infusion. DCA bears a well-documented hepatotoxic risk, while ART can…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentCase ReportToxicologychemotherapyGastroenterologylcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedizinische FakultätInternal medicineadverse effectmedicineddc:610Adverse effectCancerLiver injuryChemotherapyLeukopeniaTemozolomidebusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSurgeryClinical trial030104 developmental biologychemistryOncologyArtesunate030220 oncology & carcinogenesisadverse side effectsErythropoiesismedicine.symptombusinessmedicine.drugcomplementary and alternative medicine
researchProduct

The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community.

2021

Abstract In the last decade, a growing attention has been focused on identifying effective therapeutic strategies also in the orphan clinical setting of women with platinum-resistant disease. In this context, secondary cytoreductive surgery (SCS) remains a potential approach only in women with platinum sensitive relapse, but experimental data have been published supporting the role of SCS also in patients with platinum-resistant recurrence. In particular, surgery is emerging as a potential option in specific subgroups of women, such as those patients with low-grade serous histology, or low-volume relapse with disease located in the so-called pharmacological sanctuaries. Furthermore, contras…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentContext (language use)Antineoplastic AgentsPlatinum CompoundsDiseaseHyperthermic Intraperitoneal ChemotherapyCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineMedicineAnimalsHumansIn patientPlatinum resistantChemotherapybusiness.industryCytoreduction Surgical Proceduresmedicine.diseaseCombined Modality TherapySurgerySerous fluid030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPlatinum sensitiveFemaleNeoplasm Recurrence LocalbusinessOvarian cancerBiological features Minimally invasive surgery Personalized treatment Platinum resistant Recurrent ovarian cancer Secondary cytoreductive surgerySeminars in cancer biology
researchProduct

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (…

2020

Abstract Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models as a single agent and in combination with endocrine therapies (ET) with or without a CDK4/6 inhibitor (i). An open-label, Phase I dose escalation study of Galone and in combination with ET and P is underway in patients (pts) with locally advanced or metastatic PIK3CA-mutant solid tumors. Data from the combinations of G and L with and without P in pts with PIK3CA-mutant HR+/HER2- breast cancer are presented herein. Methods: This study (NC…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentmacromolecular substancesPalbociclibNeutropeniaGastroenterology03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineotorhinolaryngologic diseasesmedicineDexamethasoneChemotherapybusiness.industryLetrozolemedicine.diseaseHypokalemia030104 developmental biologyOncology030220 oncology & carcinogenesisPharmacodynamicsmedicine.symptombusinessmedicine.drugCancer Research
researchProduct

Repurposing of artemisinin-type drugs for the treatment of acute leukemia.

2020

Cancer treatment represents an unmet challenge due to the development of drug resistance and severe side effects of chemotherapy. Artemisinin (ARS)-type compounds exhibit excellent antimalarial effects with few side effects and drug-resistance. ARS and its derivatives were also reported to act against various tumor types in vitro and in vivo, including acute leukemia. Therefore, ARS-type compounds may be exquisitely suitable for repurposing in leukemia treatment. To provide comprehensive clues of ARS and its derivatives for acute leukemia treatment, their molecular mechanisms are discussed in this review. Five monomeric molecules and 72 dimers, trimers and hybrids based on the ARS scaffold …

0301 basic medicineCancer Researchmedicine.medical_treatmentAntineoplastic AgentsDrug resistancePharmacology03 medical and health sciencesAntimalarials0302 clinical medicineIn vivoNeoplasmsDrug DiscoverymedicineAnimalsHumansArtemisininRepurposingChemotherapyAcute leukemiabusiness.industryDrug Repositioningmedicine.diseaseIn vitroArtemisininsLeukemia030104 developmental biology030220 oncology & carcinogenesisbusinessmedicine.drugSeminars in cancer biology
researchProduct

Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients—Acute Toxicity and Treatment Quality of the Ute…

2015

The Uterus-11 trial was designed to evaluate the role of surgical staging in patients with cervical cancer before primary chemoradiation therapy (CRT). The present report provides the toxicity data stratified by the treatment arm and technique.A total of 255 patients with carcinoma of the uterine cervix (International Federation of Gynecology and Obstetrics stage IIB-IVA) were randomized to either surgical staging followed by CRT (arm A) or clinical staging followed by CRT (arm B). Patients with para-aortic metastases underwent extended field radiation therapy (RT). Brachytherapy was mandatory. The present report presents the acute therapy-related toxicities stratified by treatment arm and …

0301 basic medicineCancer Researchmedicine.medical_treatmentBrachytherapyUterine Cervical NeoplasmsCarboplatinlaw.invention0302 clinical medicineRandomized controlled trialLeukocytopenialawGermanyProspective StudiesStage (cooking)Cervical cancerRadiationRadiotherapy DosageChemoradiotherapyMiddle AgedOncology030220 oncology & carcinogenesisCarcinoma Squamous CellFemaleAdultmedicine.medical_specialtyBrachytherapyAntineoplastic AgentsContext (language use)AdenocarcinomaDisease-Free SurvivalCarcinoma AdenosquamousYoung Adult03 medical and health sciencesmedicineHumansRadiology Nuclear Medicine and imagingAgedNeoplasm Stagingbusiness.industrymedicine.diseaseSurgeryRadiation therapy030104 developmental biologyGynecologyRadiation OncologyLymph Node ExcisionRadiotherapy Intensity-ModulatedCisplatinbusinessChemoradiotherapyInternational Journal of Radiation Oncology*Biology*Physics
researchProduct

Diversity of Clinically Relevant Outcomes Resulting from Hypofractionated Radiation in Human Glioma Stem Cells Mirrors Distinct Patterns of Transcrip…

2020

Hypofractionated radiotherapy is the mainstay of the current treatment for glioblastoma. However, the efficacy of radiotherapy is hindered by the high degree of radioresistance associated with glioma stem cells comprising a heterogeneous compartment of cell lineages differing in their phenotypic characteristics, molecular signatures, and biological responses to external signals. Reconstruction of radiation responses in glioma stem cells is necessary for understanding the biological and molecular determinants of glioblastoma radioresistance. To date, there is a paucity of information on the longitudinal outcomes of hypofractionated radiation in glioma stem cells. This study addresses long-te…

0301 basic medicineCancer Researchmedicine.medical_treatmentCell150610Biologylcsh:RC254-282ArticleTranscriptome03 medical and health sciences0302 clinical medicineRadioresistanceGliomamedicineCell growthglioblastomamedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPhenotypeRadiation therapyradioresistance030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchglioma stem cellsStem cellhypofractionated radiationCancers
researchProduct

Immunomodulatory activity of microRNAs: potential implications for multiple myeloma treatment

2015

Multiple myeloma (MM) is an incurable plasma cell neoplasm accounting for about 10% of all hematologic malignancies. Recently, emerging evidence is disclosing the complexity of bone marrow interactions between MM cells and infiltrating immune cells, which have been reported to promote proliferation, survival and drug resistance of tumor cells. MicroRNAs (miRNAs) are small non-coding RNA molecules with regulatory functions in the cell, whose expression has predictive and prognostic value in different malignancies. MiRNAs are gaining increasing interest due to their capability to polarize the immune-response through different mechanisms, which include the molecular reprogramming of immune cel…

0301 basic medicineCancer Researchmedicine.medical_treatmentCellOsteoclastsAntineoplastic AgentsCD8-Positive T-LymphocytesBiologyBioinformaticsT-Lymphocytes RegulatoryImmunomodulation03 medical and health sciencesTh2 Cells0302 clinical medicineImmune systemBone MarrowDrug DiscoverymicroRNAmedicineHumansMultiple myelomamiRNAPharmacologyImmune-responseTumor immunology.MacrophagesMicroRNADendritic CellsImmunotherapyTh1 CellsPlasma cell neoplasmmedicine.diseaseGene Expression Regulation NeoplasticKiller Cells NaturalMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisImmunotherapyBone marrowMultiple MyelomaReprogrammingCurrent Cancer Drug Targets
researchProduct

Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment

2021

Simple Summary It is now accepted that CD4 T lymphocytes play an essential role in the anti-tumor response. CD4 T lymphocytes can activate and regulate several aspects of innate and adaptive immunity and participate in the rejection of tumors. Understanding the impact of the tumor, through cytokines present in the microenvironment, but also the effect of anti-cancer therapies are critical aspects of immunotherapy research aiming at improving the anti-tumor response dependent on CD4 T lymphocytes. Abstract The advancement of knowledge on tumor biology over the past decades has demonstrated a close link between tumor cells and cells of the immune system. In this context, cytokines have a majo…

0301 basic medicineCancer Researchmedicine.medical_treatmentContext (language use)ReviewBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemmedicinecancerTumor microenvironmentImmunotherapyAcquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPhenotypeCD4cytokines030104 developmental biologyCytokineOncology030220 oncology & carcinogenesisCancer researchimmunotherapyHomeostasisCancers
researchProduct

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

2018

The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance to ICP blockade. In vitro and in vivo models are eagerly needed to identify mechanisms to maximize the immune potency of ICP blockade and overcome primary and acquired resistance to ICP blockade. Vγ9Vδ2 T cells isolated from the bone marrow (BM) from multiple myeloma (MM) are excellent tools to investigate the mechanisms of resistance to PD-1 blockade and to decipher the network of mutual interactions between PD-1 and the immune suppressive tumor microenvir…

0301 basic medicineCancer Researchmedicine.medical_treatmentMini Reviewlcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemIn vivoMedicinetumor vaccinationVg9Vd2 T cells immune checkpoint blockade immunotherapy tumor vaccination multiple myelomaMultiple myelomaTumor microenvironmentVg9Vd2 T cellsbusiness.industryImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseVγ9Vδ2 T cellsImmune checkpointBlockademultiple myeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchBone marrowimmunotherapybusinessFrontiers in Oncology
researchProduct

Tumor Microenvironment And Epithelial Mesenchymal Transition As Targets To Overcome Tumor Multidrug Resistance

2020

It is well established that multifactorial drug resistance hinders successful cancer treatment. Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial-mesenchymal transition (EMT) and multidrug resistance (MDR). TME-induced factors secreted by cancer cells and cancer-associated fibroblasts (CAFs) create an inflammatory microenvironment by recruiting immune cells. CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs) and inflammatory tumor associated macrophages (TAMs) are main immune cell types which further enhance chronic inflammation. Chronic inflammation nurtures tumor-initiating/cancer stem-like cells (CSCs), induces both EMT and MDR leading to tumor re…

0301 basic medicineCancer Researchmedicine.medical_treatmentMultidrug resistanceTargeted therapyTargeted therapy0302 clinical medicineCancer-Associated FibroblastsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor-Associated MacrophagesTumor MicroenvironmentPharmacology (medical)HypoxiaTOR Serine-Threonine KinasesSmall moleculesChemotherapy ; Hypoxia ; Inflammation ; Microenvironment ; Multidrug resistance ; Small molecules ; Targeted therapy.Drug Resistance Multiple3. Good healthDNA DemethylationGene Expression Regulation NeoplasticInfectious DiseasesOncology030220 oncology & carcinogenesisInflammation MediatorsEpithelial-Mesenchymal TransitionStromal cellMicroenvironmentBiologyProinflammatory cytokine03 medical and health sciencesCell Line TumormedicineAnimalsHumansChemotherapyEpithelial–mesenchymal transitionPharmacologyInflammationTumor microenvironmentCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseHistone Deacetylase InhibitorsMultiple drug resistanceDisease Models Animal030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer research
researchProduct